ArticleFrontiers in artificial intelligence2026
Automated Nuchal Translucency analysis for early prenatal risk stratification.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuchal Translucency (NT) is a measurement taken from ultrasound images described as the gathering of fluid behind the fetus's neck, during 11-13 weeks. Increased Nuchal Translucency can lead to high risk of chromosomal abnormalities like Down Syndrome. The existing AI model may struggle to detect the subtle difference due to low resolution fetal movement, which can lead to errors in measurements and diagnosis. In addition, traditional NT measurement methods rely heavily on manual caliper placement, making the process operator-dependent and reducing consistency and automation. To address these challenges, this paper proposes an Enhanced Multi-Scale Spatial Temporal Graph Attention Network (EMSSTGAN) to predict the risk of chromosomal abnormalities in NT. Initially, the input images of NT are pre-processed using feature refinement attention network (FRANet) for denoising and Multi-Scale Attention Retinex Network (MARN) for contrast enhancement. NT detection is then performed by localizing the nuchal translucency region using bounding box annotations, followed by U-Net-based segmentation for precise extraction of the NT area. The Active Contour Model (ACM) is subsequently applied to measure the NT thickness based on boundary geometry. The thickness when compared with threshold values is used to identify the risk of chromosomal abnormalities as low, medium and high. The proposed model achieves an accuracy of 98.15%, an error of 1.85%, and a FDR of 2.44%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.